Date: 2017-12-12
Type of information: Development agreement
Compound: three OralVac immunotherapy products
Company: Allergy Therapeutics (UK) Ergomed (UK)
Therapeutic area: Allergic diseases - Immunological diseases - Respiratory diseases
Type agreement: development
Action mechanism: immunotherapy product
Disease: grass pollen allergy, tree pollen allergy, house dust mite allergy
Details:
- • On December 12, 2017, Allergy Therapeutics announced it has entered into a co-development collaboration agreement with Ergomed for the clinical development of three OralVac immunotherapy products. Allergy Therapeutics' core focus remains the convenient short course subcutaneous immunotherapy (SCIT) products, with the OralVac sublingual products providing an alternative option for patients who prefer oral products.
- To capitalise on the changing regulatory requirements in Germany, the OralVac products, which are currently sold in Europe on a named patient basis, are being registered under the new TAV (Therapieallergene-Verordnung) regulation programme managed by the Paul Ehrlich Institute in Germany. The pharmaceutical development and pre-clinical evaluation for these products has already been completed by Allergy Therapeutics. This planned OralVac clinical development expands Allergy Therapeutics' current broad SCIT clinical programme. To manage this expansion, Simon Piggott, Head of Clinical Sciences and Denise Lee, Head of Clinical Operations will lead early and late phase EU clinical development respectively, with Pieter-Jan de Kam, Clinical Director, to lead the US clinical development programme, which is focused on SCIT products and is a key part of the Group's three-pillar growth strategy.
- Under the terms of the agreement, Ergomed will progress the clinical development of OralVac products for the treatment of grass pollen, tree pollen, and house dust mite allergies.
Financial terms:
- The collaboration includes a future revenue share and reduced service fee.
Latest news:
Is general: Yes
